Streetbeat News

Stock Prices

OPTX

Trading in Syntec Optics shares has resumed. There is no additional context provided regarding the reasons for the trading halt or the implications of the resumption.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 4:23 pm

LRN

BMO Capital analyst Jeffrey Silber has reaffirmed an Outperform rating on Stride Inc. (NYSE:LRN) and increased the price target from $57 to $67, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 4:22 pm

SGD

Shares of Safe And Green Development were halted on a circuit breaker due to a rapid increase in price, with the stock surging 227.1%.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 4:21 pm

OKE

RBC Capital analyst Elvira Scotto has maintained a 'Sector Perform' rating on ONEOK (NYSE:OKE) and increased the price target from $69 to $76.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 4:16 pm

FMST

At Benzinga's 'Metals & Mining' Conference, Foremost Lithium President & CEO Jason Barnard stated that Foremost Lithium is the only hardrock lithium mining company listed on NASDAQ, which limits its competition in the market.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 4:13 pm

FIXX

Homology Medicines Inc (NASDAQ:FIXX) stock is trading lower after announcing a definitive merger agreement with Q32 Bio Inc. The all-stock transaction will result in Q32 Bio becoming a wholly owned subsidiary of Homology Medicines, with the combined company operating under the name Q32 Bio and expected to trade under the ticker 'QTTB'. Pre-merger Homology stockholders will own about 25% of the new entity, while Q32 Bio stockholders will own approximately 75%. Homology Medicines has also discontinued its R&D programs and is exploring strategic alternatives for its technology. The combined company is expected to have a cash balance of $115 million, providing a runway to mid-2026. FIXX shares have dropped 42.82% to $0.5031.

Portfolio Pulse from Vandana Singh

November 16, 2023 | 4:11 pm

FMST

FMSTW

At Benzinga's 'Metals & Mining' Conference, Foremost Lithium President & CEO Jason Barnard stated that future demand for lithium will significantly exceed current levels, indicating a bullish outlook for the lithium market.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 4:08 pm

ARCO

GYRE

KLIC

LVRO

METCB

NICE

SONO

UTI

Sonos, Inc. (NASDAQ:SONO) reported better-than-expected fourth-quarter results, with a smaller adjusted loss and higher sales than market estimates, leading to a 13.2% rise in its shares. Other companies such as Universal Technical Institute, Inc. (NYSE:UTI), NICE Ltd. (NASDAQ:NICE), Lavoro Limited (NASDAQ:LVRO), Gyre Therapeutics, Inc. (NASDAQ:GYRE), Ramaco Resources, Inc. (NASDAQ:METCB), Macy's, Inc. (NYSE:M), Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), and Arcos Dorados Holdings Inc. (NYSE:ARCO) also saw their stocks move higher on Thursday after reporting strong quarterly results or earnings.

Portfolio Pulse from Lisa Levin

November 16, 2023 | 4:05 pm

SONO

Sonos Inc (NASDAQ:SONO) stock surged after the company reported Q4 financial results that exceeded expectations and announced a $200 million stock repurchase program. Q4 revenue was $305.1 million, surpassing estimates of $299.4 million, and the Q4 EPS showed a 7 cent loss, better than the expected 18 cent loss. Gross margin increased to 42%, and the company generated $12 million in free cash flow. Despite a challenging year, CEO Patrick Spence highlighted the strength of the Sonos brand. The company's outlook for full-year 2024 revenue is $1.6 to $1.7 billion, slightly below estimates of $1.71 billion. Morgan Stanley analyst Erik Woodring maintained an Equal-Weight rating on Sonos but lowered the price target from $19 to $17.

Portfolio Pulse from Adam Eckert

November 16, 2023 | 4:03 pm

BBWI

Bath & Body Works Inc (NYSE:BBWI) reported a slight decline in Q3 FY23 sales but beat the analyst EPS estimate. Sales decreased by 2.7% Y/Y to $1.562 billion, with a marginal beat over the consensus estimate of $1.560 billion. Adjusted EPS was $0.48, surpassing the $0.35 estimate. The company announced a regular quarterly dividend of $0.20 per share. However, the Q4 outlook is weaker than expected, with projected sales decline and EPS below consensus, leading to a 5.03% drop in BBWI shares to $30.67.

Portfolio Pulse from Shivani Kumaresan

November 16, 2023 | 4:03 pm